Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Errichetti, E; Wolf, P; Khattri, S; Gorecki, P; Miller, M; Jiang, J; Han, C; Kirby, B.
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.
Acta Derm Venereol. 2024; 104:adv41053
Doi: 10.2340/actadv.v104.41053
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Wolf Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Mild psoriasis may be burdensome; if symptoms are inadequately controlled, switching therapy may be warranted. In the Phase 3 NAVIGATE trial, patients with moderate-to-severe plaque psoriasis received ustekinumab for 16 weeks. Patients with inadequate response (Investigator's Global Assessment [IGA] ≥ 2) were randomized to switch to guselkumab or continue ustekinumab. This post-hoc analysis evaluated the patient subgroup with residual mild psoriasis (IGA = 2) after initial ustekinumab therapy. Outcomes assessed included the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Psoriasis Symptoms and Signs Diary (PSSD). Initially, 871 patients received ustekinumab. At Week 16, 161 randomized patients had residual mild psoriasis (IGA = 2). Among guselkumab- vs ustekinumab-treated patients at Week 28, 59.0% vs 27.7% achieved PASI 90, and 50.0% vs 21.0% achieved DLQI 0/1. Mean changes from baseline in PSSD score were -44 vs -28 and -50 vs -32, respectively, with thresholds of -40 considered clinically meaningful. Mean changes in PSSD itch score were -4.6 vs -2.9, with reductions ≥ 4.0 considered clinically meaningful. Treatment differences were maintained/increased through Week 52. Among patients with residual mild psoriasis after 16 weeks of ustekinumab, those switching to guselkumab had greater improvements in skin clearance, health-related quality of life, and patient-reported symptoms and signs than those continuing ustekinumab.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Psoriasis - drug therapy
- Ustekinumab - therapeutic use
- Antibodies, Monoclonal, Humanized - therapeutic use, adverse effects
- Patient Reported Outcome Measures - administration & dosage
- Severity of Illness Index - administration & dosage
- Quality of Life - administration & dosage
- Drug Substitution - administration & dosage
- Dermatologic Agents - therapeutic use, adverse effects
- Treatment Outcome - administration & dosage
- Female - administration & dosage
- Male - administration & dosage
- Adult - administration & dosage
- Middle Aged - administration & dosage
- Time Factors - administration & dosage
- Remission Induction - administration & dosage
- Find related publications in this database (Keywords)
- psoriasis
- biologic therapy
- patient-reported out- come measures
- quality of life
- guselkumab
- ustekinumab